PHP157 Using the CEAC for Value Based Pricing: Don'T Change the Goalposts  by Roberts, G.
constitute a reward for manufacturers, however, various benefits have been re-
ported such as reimbursement for drugs which received an initial negative recom-
mendation (e.g. bortezomib and trabectedin, UK) and competitive advantage in the
form of better formulary position (sitagliptin & sitagliptin  metformin, USA); not
to mention the possibility of granting discounts while leaving list prices un-
touched. Considerable administrative burden is placed on health care staff due to
the diversity of existing schemes, the complexities linked with retrospective reim-
bursement, and lack of management capacity at current staffing levels.
CONCLUSIONS: Although evidence on the impact of MEs is patchy, the systematic
literature review showed that there are already lessons to be learnt. Preliminary
findings seem to suggest that MEs have indeed the potential of meeting payer,
patient, and manufacturer expectations, yet important threats such as implemen-
tation difficulties, administrative burden and lack of management capacity need to
be addressed.
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OBJECTIVES: In the UK, Patient Access Schemes (PAS) have become common in
health technology submissions, and have been instrumental in enhancing the
availability of otherwise non cost-effective treatments. Despite notable efforts to-
wards recognising and reducing the administrative impact of PAS on frontline
staff, evidence suggests that they still result in a significant burden. The study
presented here attempted to assess the burden of PAS administration, and how
this could change if and when the planned changes to the UK healthcare system
are enacted. METHODS: A literature search was conducted and freedom-of-infor-
mation requests were sent to the Patient Access Scheme Liaison Unit (PASLU) for
data on PAS administration. A questionnaire developed from our previous pilot
study on the administrative burden of PAS was distributed to hospital pharmacists
across the UK, and a call for participants was hosted on the Royal Pharmaceutical
Society website.RESULTS:Value Based Pricing (VBP) is expected to be introduced in
the UK once the current Pharmaceutical Price Regulation Scheme comes to an end.
PAS approved before this point will continue to be used, although additional PAS
may not be introduced under VBP. It is unclear from the available literature how
this will affect the role of PASLU and the administration of the remaining PAS. The
return-rate for our questionnaire was low; however, responders voiced similar
concerns to those recorded in our pilot study, namely the poor recognition of the
burden of PAS and the resources required to manage them. Responders were also
unclear about how administration of PAS would change with the move to VBP.
CONCLUSIONS:The role of PAS in the changing NHS, and the burden such schemes
could entail, is uncertain. Clear guidelines on the impact of healthcare reform are
necessary, alongside additional support to facilitate effective PAS implementation
even after VBP is introduced.
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OBJECTIVES: Pharmaceutical patents have been a useful instrument to promote
innovations in some fields. The signature of the TRIP agreement by the World
Trade Organization (WTO) in 1994 has implied the generalization of a strong patent
system. The objectives of this study is to review some existing alternatives to
patents that may both reduce their negative impact in the accessibility to new
drugs of patients from less developed countries and promote research in neglected
diseases. METHODS: We have reviewed the literature on this field and identified
different alternatives proposed by international institutions as well as by non gov-
ernmental organisations. We describe the options and assess their potential im-
pact on public health. RESULTS: There are several proposals: i) the intensive use of
exceptions and flexibility conditions of Doha=s Declaration, especially, compulsory
licensing, ii) the volunteer licensing through the “patent pool”, iii) GSPOA initiative
that targets the identification and assessment of priorities dealing with R&D re-
ferred to diseases prevalent among the developing countries, iv) the approach
based on prizes, aiming to incentive innovation through competition by separating
the cost of R&D and the price of the drug; v) the Advance Market Commitments to
ex-ante obtain the commitment to fund through donations the new agent once it
has been developed, and vi) the Priority Review Vouchers that provides incentives
to invest in drugs for neglected tropical diseases by offering a transferable voucher
to the pharmaceutical firm that allows a priority review process for the authorisa-
tion of another agent. CONCLUSIONS: Most of the solutions are partial and do not
pursue a radical change in the current patent system. In spite of these proposals,
there are still many diseases with no treatment as the market does not guarantee
a return.
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OBJECTIVES:We aimed to explore the key organizational elements and the degrees
of autonomy that is granted to Iranian corportized hospital (trustees hospitals)
affiliated to Iranian ministry of health after the Iranian health system decentral-
ization reform. METHODS: : All 18 Iranian corportized hospitals (that meet our
criteria) involved to the study. In all, 27 Hospital Top Managers were interviewed
(82% response rate). The semi-structured interview questions were developed us-
ing the Preker and Harding organizational reform Model and in-depth interviews.
The “framework” method was used for the analysis. RESULTS: Nine themes ex-
plain the key organizational elements include: decision right in “strategic”, “hu-
man resources”, “financial” and “physical resources” management, “product” and
“procurement” market exposure, “residual claimant” and “social functions”. Deci-
sion right in “strategic”, “human resources” and “physical resources” management
was very limited. The hospitals were permitted to generate revenue (fee-for- ser-
vices) but weren’t the residual claimant, completely. The hospital was exposed to
product market but limited in procurement market (ceiling payment). Hierarchical
and financial accountability were the main accountability mechanism. Several
insurance programs and governmental budget were used to protect poor people.
CONCLUSIONS:We can see a kind of unbalanced and inconsistent autonomy. More
decision right in “strategic” and “human resources” management, and procure-
ment market should be granted; and also the hospital needs to be the residual
claimant. Government needs a regulatory and accountability mechanism to guar-
antee hospitals performance and balance the revenue generating and social values
objectives.
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OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC
and the allocation of $1.1 billion for comparative effectiveness research by the
United States, are strong indicators of trends in pricing and reimbursement that
are likely to be observed in the future. To gain an additional insight into these
trends, we analyzed the cost effectiveness studies for the top twenty highest selling
drugs ($90-100B worldwide sales). METHODS: The Top 20 drugs were selected
based on their worldwide sales. For this analysis, we segmented these drugs into
categories as primary care, specialty, small molecules, biologics, therapy areas and
availability of generic alternatives. We analyzed the cost effectiveness studies that
were published in peer-reviewed journals. Search was conducted using generic
names of the drugs and the phrase cost effectiveness in abstract of the published
study. RESULTS:During 2005-2010, the number of published studies on cost effec-
tiveness have increased by more than 30%. There is a large variability in CERs for
same drugs for different indications, in some cases also varying by biomarkers.
Primary care drugs had lower and less variable CERs than specialty drugs. Varia-
tions also exist in methodology used by different groups in modeling cost effec-
tiveness, especially for time horizon and comparator. Majority of primary care
drugs were modeled for a time horizon of 35-40 years or lifetime to demonstrate
cost effectiveness. CONCLUSIONS: This analysis shows the range, variability and
methods used for calculation of ICER values for these high budget impact drugs and
provides lessons for executives and policy makers.
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OBJECTIVES: Cancer drugs are the world’s highest selling category of therapeutic
products. Due to their premium price and budget impact, several new drug reim-
bursement models have been implemented worldwide by public and private pay-
ers. These models have potential implications for coverage and reimbursement of
all branded products. This study reviewed recent cancer drug reimbursement mod-
els and developed lessons and implications for future products. METHODS: Re-
viewed cancer drug reimbursement schemes in developed and emerging markets.
Interviewed payers and KOLs to develop lessons and implications for future
products. RESULTS: Public and private payers worldwide have implemented sev-
eral new models for cancer drug reimbursement to manage budgets and control
costs. In the US, private payers are piloting single source compendia and third party
protocols (eg. P4 Oncology) to limit off-label use of cancer drugs. In the UK, NICE has
successfully negotiated lower price and discounts for first few cycles of therapy. In
Italy, AIFA has implemented registry based patient access for cancer drugs. In
India, several manufacturers have implemented novel pricing strategy for first few
cycles of therapy. In Germany, IQWIG has proposed to use correlations between
surrogate endpoints and patient relevant outcomes to determine value of cancer
drugs. Due to increased cost pressure on payers, such models are likely to inspire
novel reimbursement schemes for other branded products.CONCLUSIONS:Cancer
drug reimbursement models are setting new benchmark for payers to manage
access and control costs. These models have significant implications for other
expensive branded products.
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ISSUE One approach under consideration for the proposed value based pricing of
pharmaceutical is the UK is to have different willingness to pay thresholds. How-
ever these are problematic to define, lack transparency and not readily understood
by the wider public. OVERVIEW Different willingness to pay thresholds have been
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suggested as a way to incorporate uncertainty in the measurement of societal value
when setting the price of a new pharmaceutical. An alternative approach would be
may be to define one WTP threshold and then accept different levels of risk or a
different probability of being cost-effective at that threshold. For example innova-
tive products, cancer drugs and drugs for orphan diseases could be assessed with a
more flexible approach based on the system already in place. For example we may
be willing to accept only a 20% probability that the medicine is cost-effective at
£30,000/QALY. In theory, where there is greater uncertainty, the ICER could be any
value higher than 30K but at least there is a chance that the treatment is ‘cost-
effective’ for a proportion of patients. Similarly in disease areas where there is low
unmet need we could set the barrier higher and these medicines should have a
probability greater than 80% of being cost-effective at that threshold. So we have
one set of goalposts, if you shoot from the penalty spot you have to score but from
the half way line we can accept a few misses. CONCLUSION As a society we can
remain consistent in what we are willing to pay for a unit of health benefit. For
treatments where there is a high unmet need and an added benefit is perceived we
can afford to be more risky.
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OBJECTIVES: There are many thresholds for the value of a Quality-adjusted Life-
Year (QALY), varying between countries and jurisdictions, without however clear
evidence of the valuation process. The objective of this study was to systematically
review the literature for the evidence on the monetary valuation of a QALY.
METHODS: OVID MEDLINE® was independently searched for 1996-2011 by two
reviewers using the keywords [QALY or (Quality and Adjusted and Life and Years)]
and [Monetary and (Valuation or Value or (Value estimation) or (Value determina-
tion)]. Discrepancies in inclusion and data extraction were handled through agree-
ment. Included articles had to have applied a technique to determine the monetary
value of a QALY, either on patients, the public, both, or through other statistical
means. RESULTS: From 174 articles yielded by the review, 6 met the criteria, 4 were
European studies (Denmark, The Netherlands, the UK and Spain), and 1 from each
the USA and China. None of them targeted only patients for the valuation, 4 tar-
geted the general public, 2 studies focused on both. Three studies targeted a spe-
cific disease while 3 did not limit to any condition. Willingness-to-pay technique
was the most common valuation method (5/6) and QALYs were determined with
various direct or indirect elicitation measures. The average value for a QALY varied
from the equivalent of less than USD$5,000 to more than USD$100,000. While some
authors stated that preference valuation can lead to meaningful QALY values, the
majority agreed on the large variability of the results depending on many factors
such as income level, age, gender or disease condition and method of elicitation.
CONCLUSIONS: The literature on monetary valuation of a QALY is very limited,
and the range of reported values is very wide and can be differently impacted by the
survey tools used and by the characteristics of the population of interest.
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OBJECTIVES: Translational Research (TR) comprises activities aiming at the gener-
ation of biomedical knowledge, its transfer into clinical practice, and the take-up of
research questions in biomedical research. It is described as a non-unidirectional
process with mutual interexchange between different development stages. Health
Technology Assessment (HTA) is predominantly located in later phases of the
translational process where implementation, diffusion and dissemination of a
technology are focused. METHODS: Within the ELSA-GEN research collaboration,
institutional and social aspects of TR in genomic medicine were investigated (TRi-
Gen). We performed literature search and expert interviews to build a concept that
captures the potential feed-back loops HTA is involved in, and the characteristics
of interactions with actors in TR. RESULTS: Traditionally, HTA is applied on a
‘societal level’ and aims at public and clinical decision-makers. But it can also be
performed on a ‘project level’ to contribute in early phases of development by
evaluating premature technologies. In that context, interactions of HTA with man-
ufacturers, clinicians and, to a less extent, (basic) researchers become relevant.
Interactions are facilitated and shaped by specific organizational and institutional
structures. These ‘modes of interaction’ include approval and reimbursement reg-
ulations, funding structures, stakeholder involvement in the HTA process, and
prioritization of assessment topics. Formal prerequisites are not fulfilled between
all TR players and phases. Our analysis indicates that where they are not in place,
the full potential of HTA for the generation and translation of evidence in TR is not
met. Feed-back of HTA results regarding evidence gaps into the research agenda
could be strengthened. CONCLUSION: HTA can be regarded not only as a tool to
promote successful TR, but also as an additional actor that influences the transla-
tion of a technology in different stages. Organizational and institutional structures
need to be considered to foster its impact on the translation process.
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European Medicines Agency, London, UK
Attaining good patient health outcomes (HO) is the underlying purpose of any
health care intervention, including drug therapy. The measurement of HO is the
basis for evaluating the quality of health services, and a key element in determin-
ing the value of health interventions. Along with effectiveness, long term safety is
an important component of HO of new authorised human medicines. The explicit
assessment of the sustained benefit-risk trade-off of new authorised products
must be undertaken to ensure that unintended harmful consequences are not
offsetting the intended clinical benefits. Spontaneous reporting schemes provide a
means of continuous surveillance of medicines that is important for raising early
signals of safety concerns, but ad-hoc post-authorisation safety studies (PASS) may
be necessary to evaluate the safety of medicines more accurately. The European
Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) is
an initiative led by the European Medicines Agency aimed at further strengthening
post- authorisation medicines research in Europe by facilitating the conduct of
multi-centre, independent PASS focusing on safety and on benefit/risk. Specifi-
cally, ENCePP provides a unique point of access for all involved stakeholders seek-
ing collaboration for the commissioning or the conduct of PASS. This is achieved by
offering access to available expertise and research experience in the fields of phar-
macoepidemiology and pharmacovigilance across Europe brought together into a
functioning network of excellence. It is anticipated that ENCePP will add to knowl-
edge and the EU capacity to conduct PASS studies in the light of shared methodol-
ogies and expertise. In doing so, ENCePP can serve as a bridge between medicines
regulation and HO research in supporting risk/benefit management planning to
minimise adverse events and maximise the benefit of marketed medicines.
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OBJECTIVES: Russia has a severe access to medicines problem. Of the 142 million
people in Russia, only 20 million are eligible for outpatient medicines coverage as
part of the Supplementary Medicines Cover (DLO) programme. More than half of
the eligible opt-out for cash. The current government’s goal is to eventually estab-
lish universal outpatient medicines coverage. This study explores pharmaceutical
policy options for Russia to improve efficiency and access to medicines. We employ
a conceptual framework to explain Russia’s priorities and the weighing of each
health policy component in developing policy approaches. Based on Russia’s par-
ticular policy needs, as well as economic environment and market structure, we
provide policy options anchored in lessons from the European Union and the
United States. Overall, Russia requires more efficient pricing policies to increase
coverage and access to medicines. METHODS: Our findings suggest that, although
generic market shares are high, there is room for lower generic prices. In order to
address this inefficiency, we propose the adoption of tenders for high-selling off-
patent molecules, and free pricing for molecules with sufficient market competi-
tion. The combination of external price referencing and tenders at the wholesaler
level for in-patent markets is confusing, and in order to make originator pricing
more efficient, we suggest health technology assessment. As universal coverage is
a priority, additional funding will be required with potential sources coming from
co-payments or abolishing the possibility of opting-out of the DLO for cash. Im-
proving efficiency in the. RESULTS: Russian pharmaceutical market will make an
additional monetary unit to be invested in medicines rather than somewhere else
in the policy environment have a positive effect on social welfare. CONCLUSIONS:
Russia can achieve greater efficiency and lower prices in its pharmaceutical mar-
ket, which would contribute to reaching the goal of universal outpatient medicines
coverage.
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OBJECTIVES: Understand the impact of AMNOG on pharmaceutical pricing trends.
METHODS: The reforms implemented by AMNOG were reviewed by analysing re-
cent changes in German healthcare system. A basket of five branded products was
chosen to analyse pricing trends for past four quarters (Q3 2010, Q4 2010, Q1 2011,
Q2 2011). Quarterly increase or decrease in prices were compared for all five drugs.
RESULTS: AMNOG introduced major changes in German healthcare system. Tra-
ditionally Germany was one of the highest priced pharmaceutical markets in Eu-
rope, with significant price inflation. However, since the implementation of AM-
NOG, there has not been any price inflation for the selected five branded products.
Our analysis shows that prices have either declined or stayed steady during past
four quarters. Some products such as Aranesp saw significant price decreases
(5-9% per quarter), driven by AMNOG and by launch of cheaper biosimilar products.
Other products show deflation of 0.6-1% per quarter. CONCLUSIONS: Pharmaceu-
tical pricing landscape in Germany has significantly altered since the implemen-
tation of AMNOG. Newer products would need to demonstrate improvement in
comparative efficacy to command premium launch price or increase in price.
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